Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma

Clinical Rheumatology

Volumn 15, Issue 4, 1996, Pages 347-352

  Laroche, M ^a,c   Attal, M ^b   Dromer, C ^b  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

^c Service de Rhumatologie   (France)

Author keywords

Calciuria creatinine ratio; Histomorphometry; Myeloma; Osteocalcin

Indexed keywords

CREATININE; OSTEOCALCIN;

ADULT; AGED; ARTICLE; BONE REMODELING; CALCIUM URINE LEVEL; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MORPHOMETRICS; MYELOMA; PARAPROTEINEMIA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DISEASES; BONE REMODELING; CALCIUM; CREATININE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; OSTEOCALCIN; PARAPROTEINEMIAS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY;

EID: 0029943164     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02230356     Document Type: Article

References (26)

1. Mundy, G.R., Raisz, L.G., Cooper, R.A. et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974, 291, 1041-1046.
2. Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Sany, J., Baldet, P., Alexandre, C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989, 7, 1909-1914.
3. Bataille, R., Chappard, D., Klein, B. Mechanisms of bone lesions in muliple myeloma. Hematol Oncol 1992, 6, 285-295.
4. Laroche, M., Cantagrel, A., Degraeve, J., Mazieres, B., Arlet, J. Avantages et inconvenients de l'étude de l'excrétion urinaire à jeun du calcium et du phosphore comparée aux dosages de 24 heures. Sem Hop Paris, 1988, 64, 81-84.
5. Nordin, B.E.C. Diagnosis procedures in disorders of calcium metabolism. Clin Endocrinol, 1978, 8, 56-67.
6. Parfitt, A.M., Drezner, M.K., Glorieux, F.H. et al. Bone histomorphometry: standardization of nomenclature symbols and units. J Bone Min Res 1987, 2, 595-610.
7. Meunier, P.J., Courpron, P., Edouard, C. et al. Physiological senile involution and pathological rarefaction of bone. Quantitative and comparative histological data. In: Clinics in Endocrinology and Metabolism, London, England, Saunders, 1973, 239-255.
8. Kyle, A. Classification and diagnosis of monoclonal gammopathies. In: Manual of Clinical Laboratory Immunology. Ed.: Rose, N.R., Friedman, H., Fahey, K., Washington (DC) American Society for Microbiology 1984, 152-167.
9. Alexandre, C., Bataille, R., Chappard, D., Dessauw, P., Sany, J., Riffat, G. Apport de la biopsie osseuse avec histomorphométrie dans l'évaluation d'une gammapathie monoclonale. Rev Rhum 1987, 54, 717-721.
10. Kyle, A. "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc 1993, 68, 26-36.
11. Durie, B.G.M., Salmon, S.E. A clinical staging system for multiple myeloma. Cancer, 1975, 842-854.
12. Dimopoulos, M.A., Moulopoulos, A., Smith, T., Delassale, K.B., Alexanian, R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993, 94, 57-61.
13. Taube, T., Beneton, M.N.C., Mc Closley, E.V., Rogers, S., Greaves, M., Kanis, J.A. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992, 49, 192-198.
14. Valentin-Opran, A., Charbon, S.A., Meunier, P.J. et al. Quantitative histology of myeloma-induced bone changes. Br J Haematol 1982, 52, 601-610.
15. Bataille, R., Delmas, P.D., Chappard, D., Sany, J. Abnormal serum bone Gla protein levels in multiple myeloma. Cancer 1990, 66, 167-172.
16. Brown, J.P., Delmas, P.D., Malaval, L., Edouard, C., Chapuy, M.C., Meunier, P.J. Serum bone Gla-protein: a specific marker for bone formation in post-menopausal osteoporosis. Lancet 1984, 1, 1091-1093.
17. Delmas, P.D., Demiaux, B., Malaval, J. et al. Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia: comparison with bone histomorphometry. J Clin Invest 1986, 77, 985-991.
18. Williams, A.T., Shearer, M.J., Oyeyi, J. et al. Serum osteocalcin in the management of myeloma: Eur J Cancer, 1993, 29A, 140-142.
19. Frost, H.M. Tetracyclin-based histological analysis of bone remodelling. Calc. Tissue Res 1969, 3, 211-237.
20. Baron, R., Chakraborty, D., Vhaterjee, W. et al. Biology of the osteoclast. In: Physiology and Pharmacology of Bone. Eds.: G.R. Mundy and T.J. Martin, Springer New-York, 1993.
21. Delmas, P.D., Charon, S., Chapuy, M.C. et al. Long-term effects of dichloromethylene diphosphonate on skeletal lesions in multiple myeloma Metab Bone Dis Rel Res 1982, 4, 163-168.
22. Lahtinen, R., Laasko, M., Palva, I., Virkkunen, P., Elomaa, I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet, 1992, 340, 1049-1052.
23. Merlini, G., Attardo-Parinello, G., Piccinini, L. et al. Long-term effects of parenteral dichloromethylene biphosphonate on bone disease in myeloma patients treated with chemotherapy. Hematol Oncol. 1990, 8, 23-30.
24. Roux, C., Ravaud, P., Cohen-Solal, M. et al. Biologic, histologic and densitometric effects of oral risedronate on bone patients with multiple myeloma. Bone 1994, 15, 41-49.
25. Harley, J.B., Schilling, A., Glidewell, O. Ineffectiveness of fluoride therapy in multiple myeloma. N Engl J Med 1975, 286, 1283-1288.
26. Kyle, R.A., Jowsey, J., Kelly, P.J., Taves, D.R. Multiple myeloma bone disease. N Engl J Med 1975, 293, 13341338.